Cronin E, Cushen B
Breathe (Sheff). 2025; 21(1):240099.
PMID: 40007528
PMC: 11851148.
DOI: 10.1183/20734735.0099-2024.
Enomoto Y, Kusaka K, Sato K, Takeda K, Kawashima M, Morio Y
Respir Med Case Rep. 2025; 53:102174.
PMID: 39980612
PMC: 11840548.
DOI: 10.1016/j.rmcr.2025.102174.
Zeder K, Sassmann T, Foris V, Douschan P, Olschewski H, Kovacs G
Int J Cardiol Congenit Heart Dis. 2024; 17:100519.
PMID: 39711774
PMC: 11658424.
DOI: 10.1016/j.ijcchd.2024.100519.
Kern A, Park D, Fuge J, Hohlfeld J, Wacker F, Hoeper M
Eur Radiol. 2024; .
PMID: 39645621
DOI: 10.1007/s00330-024-11209-1.
Johnson S, Wan E, San Jose Estepar R, Nardelli P, Pistenmaa C, Piccari L
Ann Am Thorac Soc. 2024; 22(2):175-180.
PMID: 39556097
PMC: 11808541.
DOI: 10.1513/AnnalsATS.202408-878PS.
The relation between socioeconomic status and invasive haemodynamics at evaluation for advanced heart failure.
Larsson J, Kristensen S, Deis T, Warming P, Schou M, Kober L
ESC Heart Fail. 2024; 12(1):477-486.
PMID: 39344872
PMC: 11769609.
DOI: 10.1002/ehf2.15089.
Pulmonary hypertension associated with lung diseases.
Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E
Eur Respir J. 2024; 64(4).
PMID: 39209469
PMC: 11525344.
DOI: 10.1183/13993003.01200-2024.
Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry.
Tello K, Yogeswaran A, Majeed R, Kiely D, Lawrie A, Brittain E
Chest. 2024; 167(1):224-240.
PMID: 39182575
PMC: 11864130.
DOI: 10.1016/j.chest.2024.08.016.
Evaluating the impact of type 2 diabetes mellitus on pulmonary vascular function and the development of pulmonary fibrosis.
Mzimela N, Dimba N, Sosibo A, Khathi A
Front Endocrinol (Lausanne). 2024; 15:1431405.
PMID: 39050565
PMC: 11266053.
DOI: 10.3389/fendo.2024.1431405.
Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET.
Stoleriu M, Pienn M, Joerres R, Alter P, Fero T, Urschler M
Int J Chron Obstruct Pulmon Dis. 2024; 19:1515-1529.
PMID: 38974817
PMC: 11227296.
DOI: 10.2147/COPD.S458905.
Predictors of Mortality in Pulmonary Hypertension-Associated Chronic Lung Disease.
Pescatore J, Bittner M, DAlonzo G, Weaver S, Gayen S
J Clin Med. 2024; 13(12).
PMID: 38929999
PMC: 11205208.
DOI: 10.3390/jcm13123472.
Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response.
Johnson S, Wang R, Winter M, Gillmeyer K, Zeder K, Klings E
ERJ Open Res. 2024; 10(3).
PMID: 38770008
PMC: 11103711.
DOI: 10.1183/23120541.00959-2023.
Abnormal heart rate responses to exercise in non-severe COPD: relationship with pulmonary vascular volume and ventilatory efficiency.
Shi M, Qumu S, Wang S, Peng Y, Yang L, Huang K
BMC Pulm Med. 2024; 24(1):183.
PMID: 38632576
PMC: 11022473.
DOI: 10.1186/s12890-024-03003-y.
The role of vasculature and angiogenesis in respiratory diseases.
Ackermann M, Werlein C, Plucinski E, Leypold S, Kuhnel M, Verleden S
Angiogenesis. 2024; 27(3):293-310.
PMID: 38580869
PMC: 11303512.
DOI: 10.1007/s10456-024-09910-2.
Elevated pulmonary vascular resistance is associated with increased lung transplant waitlist mortality among patients with chronic obstructive pulmonary disease and pulmonary hypertension: a retrospective cohort analysis.
Gayen S, Zulty M, Criner G
Respir Res. 2024; 25(1):79.
PMID: 38321451
PMC: 10848503.
DOI: 10.1186/s12931-024-02674-9.
Improving Prognostication in Pulmonary Hypertension Using AI-quantified Fibrosis and Radiologic Severity Scoring at Baseline CT.
Dwivedi K, Sharkey M, Delaney L, Alabed S, Rajaram S, Hill C
Radiology. 2024; 310(2):e231718.
PMID: 38319169
PMC: 10902594.
DOI: 10.1148/radiol.231718.
Efficacy and Safety of Bisoprolol in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
Feng Z, Zhang L, Wang Y, Guo H, Liu J
Int J Chron Obstruct Pulmon Dis. 2023; 18:3067-3083.
PMID: 38152590
PMC: 10752233.
DOI: 10.2147/COPD.S438930.
Pulmonary Vasodilator Therapy in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (Severe PH-COPD): A Systematic Review and Meta-Analysis.
Elkhapery A, Hammami M, Sulica R, Boppana H, Abdalla Z, Iyer C
J Cardiovasc Dev Dis. 2023; 10(12).
PMID: 38132665
PMC: 10743410.
DOI: 10.3390/jcdd10120498.
Utility of Cardiopulmonary Exercise Testing in Chronic Obstructive Pulmonary Disease: A Review.
Behnia M, Sietsema K
Int J Chron Obstruct Pulmon Dis. 2023; 18:2895-2910.
PMID: 38089541
PMC: 10710955.
DOI: 10.2147/COPD.S432841.
Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis.
Weiss T, Near A, Zhao X, Ramey D, Banerji T, Xie H
BMC Pulm Med. 2023; 23(1):455.
PMID: 37990203
PMC: 10664271.
DOI: 10.1186/s12890-023-02698-9.
